ZAGBEMIZ Trademark

Medicines for human purposes, namely, medicines for the treatment of cancer, cardiovascular diseases, hematologic diseases, neurological diseases, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin, congenital bleeding disorders and acquired bleeding disorders, disorders due to a deficiency of a coagulation factor, disorders due to the presence of acquired inhibitors to a coagulation factor, hematologic disorders, hemorrhagic disorders, Von Willebrands' disease, disorders resulting from anticoagulant therapy with a vitamin-K antagonist, hereditary platelet disorders, vitamin K epoxide reductase C1 deficiency, gamma-carboxylase deficiency, bleeding associated with trauma, injury, and surgery, thrombosis, thrombocytopenia, stroke, coagulopathy, disseminated intravascular coagulation (DIC), Bernard Soulier syndrome, Glanzman thromblastemia, storage pool deficiency, and hemophilia; pharmaceutical preparations and substances for the treatment of viral diseases, metabolic diseases, endocrine diseases, musculoskeletal diseases, cardiovascular diseases, hematologic diseases, cardiopulmonary diseases, genitourinary diseases, sexual dysfunction, oncological diseases, hepatological diseases, ophthalmic diseases, respiratory diseases, neurological diseases, gastrointestinal diseases, hormonal diseases, dermatological diseases, coagulation disorders, diseases of the blood and blood-forming organs, psychiatric and immune system related diseases and disorders, congenital bleeding disorders and acquired bleeding disorders, disorders due to a deficiency of a coagulation factor, disorders due to the presence of acquired inhibitors to a coagulation factor, hematologic disorders, hemorrhagic disorders, Von Willebrands' disease, disorders resulting from anticoagulant therapy with a vitamin-K antagonist, hereditary platelet disorders, vitamin K epoxide reductase C1 deficiency, gamma-carboxylase deficiency, bleeding associated with trauma, injury, and surgery, thrombosis, thrombocytopenia, stroke, coagulopathy, disseminated intravascular coagulation (DIC), Bernard Soulier syndrome, Glanzman thromblastemia, storage pool deficiency, and hemophilia; diagnostic preparations for medical purposes; dietetic foods and beverages adapted for medical use; depuratives for the body; veterinary pharmaceutical compounds for equine use to treat conditions of the leg, hoof, ear, nose and throat; pesticides; first aid kits; dental abrasives.